Status:
COMPLETED
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Cancer
Eligibility:
All Genders
Up to 25 years
Brief Summary
This study will construct tissue microarrays (TMAs) pertaining to childhood cancer. TMA technology is a recently developed one that allows for evaluating hundreds of tissue samples simultaneously on t...
Detailed Description
Background: Cancer drug discovery is now focused on identifying molecularly targeted drugs that are more selective and specific for proteins and signaling pathways that are directly involved in tumori...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Twenty representative formalin-fixed, paraffin-embedded specimens for each of 17 histologically distinct pediatric solid tumors will be collected from the pathology departments of selected Pediatric Phase I Consortium collaborators.
Exclusion
Key Trial Info
Start Date :
September 7 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 11 2014
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT00340522
Start Date
September 7 2004
End Date
August 11 2014
Last Update
December 16 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892